Breast Cancer (BrCa) is a hormone-related malignancy. Current treatment plans target the hormone receptors, which also act as prognostic indicators. However, despite the advancement in treatment modalities, BrCa continues to be one of the most frequently diagnosed cancer in the world and the leading cause of cancer-related casualties in females. Accumulating evidence suggests that androgen signalling plays an important role in BrCa development and progression. With more than 60-80% of tumors expressing the Androgen Receptor (AR), the transcription factor has emerged as a potential prognostic marker and therapeutic target. We investigate the role of AR in the pathogenesis of BrCa using an integrated molecular approach. Our study aims to elucidate the role of AR as a probable therapeutic target in BrCa and help in understanding the genomic classification and characterization of BrCa amongst Indian women.
HONORS AND AWARDS
| Award | Awarding agency | Timeline |
|---|---|---|
| Second prize in poster and third prize in the quiz competition | Oncovision 2022 | November 2022 |
| Young Investigator Award | Korean Society of Medical Oncology, South Korea | September 2022 |
| Internation Travel grants | SERB, AIIMS CSIR, & DBT, Govt of India | March-September 2022 |
| Member | European Society for Medical Oncology (ESMO) | November 2022 |
| Member-in-training | American Society of Clinical Oncology (ASCO) | October 2020 |
| Associate member | American Association for Cancer Research (AACR) | July 2020 |
| Member | American Society for Clinical Pathology (ASCP) | September 2020 |
| Junior Research Fellowship (CSIR-JRF) & (CSIR-NET) in Life sciences | Council of Scientific and Industrial Research (CSIR) | June 2018 |
| IELTS Academic overall band score 7.5 (L-8.5, R-8, W-6.5, S-7) | British Council | February 2018 |
| Graduate Aptitude Test in Engineering (GATE) Life Sciences | IIT Roorkee | March 2017 |
| Merit-cum-Means Scholarship | South Asian University | Aug 2014 – May 2016 |